Interchangeability of blood‐based biomarkers and PET to identify Alzheimer's disease pathology

20260 citationsJournal Articlegold Open Access

Authors

J. Wang · Eli Lilly (United States)

Joel B. Braunstein · C2N Diagnostics (United States)

Robin Wolz · Ixico (United Kingdom)

Laura Harper · Eli Lilly (United States)

Tricia Locascio · Eli Lilly (United States)

Holly E McPherson · Eli Lilly (United States)

Richard Mohs ·

Abstract

Interchangeability of plasma-based tests and amyloid-PET stratifications was demonstrated.Non-inferiority of plasma-based biomarkers to amyloid-PET for identifying patients with AD pathology was observed.High agreement between plasma-based test stratification and florbetapir-PET expert visual read was observed.

Topics & Keywords

Dementia and Cognitive Impairment Research Medical Imaging Techniques and Applications S100 Proteins and Annexins

Publication Details

Published in: Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring

Volume 18, Issue 1, pp. e70196-e70196

DOI: 10.1002/dad2.70196

Field-Weighted Citation Impact: 0.00

Command Palette

Interchangeability of blood‐based biomarkers and PET to identify Alzheimer's disease pathology

Authors

Abstract

Topics & Keywords

Publication Details